Section Arrow
Quote
ARQT.NASDAQ
- Arcutis Biotherapeutics
Quotes are at least 15-min delayed:2026/05/25 20:11 EDT
Regular Hours
Last
 20.86
-0.15 (-0.71%)
Day High 
21.41 
Prev. Close
21.01 
1-M High
24.27 
Volume 
1.16M 
Bid
20
Ask
21.6
Day Low
20.63 
Open
21.01 
1-M Low
19.295 
Market Cap 
2.63B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 20.87 
20-SMA 21.97 
50-SMA 22.76 
52-W High 31.77 
52-W Low 12.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.02/0.79
Enterprise Value
2.74B
Balance Sheet
Book Value Per Share
1.52
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
376.07M
Operating Revenue Per Share
0.39
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
GOVXGeoVax Labs Inc.3.64+0.89+32.36%-- 
MTVAMetaVia Inc.3.85+0.98+34.15%-- 
AKTXAkari Therapeutics Plc18.27+13.13+255.45%-- 
LIMNLiminatus Pharma Inc0.1694-0.0766-31.14%-- 
IOVAIovance Biotherapeutics4.11+0.41+11.08%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.